Immunome Inc is a biopharmaceutical company focused on developing innovative antibody therapies for the treatment of cancer and other diseases. The company leverages its proprietary platform to identify and isolate antibodies from human immune cells, which are then engineered to target specific antigens linked to various diseases. By harnessing the body's natural immune response, Immunome aims to create therapies that are both effective and safe, with a commitment to improving patient outcomes in oncology and beyond. Through its research and development efforts, Immunome is dedicated to advancing the field of immunotherapy and addressing unmet medical needs. Read More
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $400 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of its common stock. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
ENDRA Life Sciences (NASDAQ: NDRA) is emerging as a differentiated small-cap opportunity by combining breakthrough medical imaging innovation with a next-generation treasury strategy designed to improve capital efficiency and accelerate growth. The company, developer of the TAEUS® (Thermo-Acoustic Enhanced UltraSound) system for liver disease, is addressing one of healthcare’s largest unmet needs while modernizing how it manages and deploys corporate capital.
Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type of connective tissue tumor.
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors.
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 88,000 shares of common stock to four new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s management will participate in the following investor conferences:
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September 30, 2025, and provided a business update.
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 19,000 shares of common stock to three new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on Tuesday, Nov. 11, 2025 at 8:30 a.m. ET.
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary antibody-drug conjugate (ADC) payload HC74 overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity.
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Oct. 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 69,000 shares of common stock to 5 new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced a research collaboration agreement with Immunome, Inc. (NASDAQ: IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed.
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Sept. 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 117,000 shares of common stock to 8 new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, Sept. 9, 2025 at 1:00 p.m. Eastern Time.
